Stay updated on Brentuximab Vedotin Plus Pembrolizumab Clinical Trial

Sign up to get notified when there's something new on the Brentuximab Vedotin Plus Pembrolizumab Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Brentuximab Vedotin Plus Pembrolizumab Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    The clinical trial record for brentuximab vedotin plus pembrolizumab in metastatic solid tumors is displayed, including study details, participant criteria, treatment and outcome measures, and participating locations. The record indicates that the study is completed and no longer recruiting.
    Difference
    82%
    Check dated 2026-11-07T11:46:49.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-31T12:16:21.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    The record for the completed Phase 2 trial of brentuximab vedotin with pembrolizumab is now displayed, with study design, eligibility criteria, outcomes, participating locations, and data-sharing details.
    Difference
    85%
    Check dated 2026-10-24T14:50:30.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision indicator changes from v3.7.1 to v3.7.2 while the page remains a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-17T14:42:10.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The footer revision identifier was updated from v3.7.0 to v3.7.1. The page still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-10T15:39:00.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    A new revision tag Revision: v3.7.0 is shown, and a large set of footer-related and sponsor/data-sharing texts is removed, including contact prompts and IPD sharing details. This changes the visible footer content and disclosure elements while leaving the core study information intact.
    Difference
    17%
    Check dated 2026-09-19T19:10:41.000Z thumbnail image

Stay in the know with updates to Brentuximab Vedotin Plus Pembrolizumab Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Brentuximab Vedotin Plus Pembrolizumab Clinical Trial page.